Xeris Biopharma: Q1 earnings snapshot. CHICAGO (AP) - CHICAGO (AP) - Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported first-quarter net income of $2.2 million. On a per-share basis, the Chicago-based company said it had profit of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was breakeven on a per-share basis. The company posted revenue of $83.1 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $80 million. Xeris Biopharma expects full-year revenue in the range of $380 million to $390 million. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.